Xeris Biopharma Inc. (XERS)
Xeris Biopharma Statistics
Share Statistics
Xeris Biopharma has 149.08M shares outstanding. The number of shares has increased by 6.14% in one year.
| Shares Outstanding | 149.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 138.51M |
| Failed to Deliver (FTD) Shares | 1K |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 9.52M, so 6.38% of the outstanding shares have been sold short.
| Short Interest | 9.52M |
| Short % of Shares Out | 6.38% |
| Short % of Float | 6.73% |
| Short Ratio (days to cover) | 5.53 |
Valuation Ratios
The PE ratio is -5.2 and the forward PE ratio is -14.55.
| PE Ratio | -5.2 |
| Forward PE | -14.55 |
| PS Ratio | 1.97 |
| Forward PS | null |
| PB Ratio | -47.71 |
| P/FCF Ratio | -6.56 |
| PEG Ratio | n/a |
Enterprise Valuation
Xeris Biopharma Inc. has an Enterprise Value (EV) of 485.28M.
| EV / Earnings | -7.8 |
| EV / Sales | 2.96 |
| EV / EBITDA | -20.45 |
| EV / EBIT | -11.03 |
| EV / FCF | -9.85 |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of -33.79.
| Current Ratio | 1.64 |
| Quick Ratio | 1.23 |
| Debt / Equity | -33.79 |
| Total Debt / Capitalization | 103.05 |
| Cash Flow / Debt | -0.21 |
| Interest Coverage | -1.65 |
Financial Efficiency
Return on equity (ROE) is 9.18% and return on capital (ROIC) is -19.4%.
| Return on Equity (ROE) | 9.18% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -19.4% |
| Revenue Per Employee | 434.79K |
| Profits Per Employee | -165.13K |
| Employee Count | 377 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 0.74 |
Taxes
| Income Tax | -1.25M |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by 32.37% in the last 52 weeks. The beta is 1.28, so Xeris Biopharma 's price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | 32.37% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 2.65 |
| Relative Strength Index (RSI) | 41.99 |
| Average Volume (20 Days) | 1.66M |
Income Statement
In the last 12 months, Xeris Biopharma had revenue of 163.91M and earned -62.26M in profits. Earnings per share was -0.45.
| Revenue | 163.91M |
| Gross Profit | 135.27M |
| Operating Income | -44.01M |
| Net Income | -62.26M |
| EBITDA | -23.73M |
| EBIT | -44.01M |
| Earnings Per Share (EPS) | -0.45 |
Balance Sheet
The company has 67.45M in cash and 229.19M in debt, giving a net cash position of -161.74M.
| Cash & Cash Equivalents | 67.45M |
| Total Debt | 229.19M |
| Net Cash | -161.74M |
| Retained Earnings | -617.02M |
| Total Assets | 321.10M |
| Working Capital | 71.79M |
Cash Flow
In the last 12 months, operating cash flow was -47.02M and capital expenditures -2.26M, giving a free cash flow of -49.29M.
| Operating Cash Flow | -47.02M |
| Capital Expenditures | -2.26M |
| Free Cash Flow | -49.29M |
| FCF Per Share | -0.36 |
Margins
Gross margin is 82.52%, with operating and profit margins of -26.85% and -37.98%.
| Gross Margin | 82.52% |
| Operating Margin | -26.85% |
| Pretax Margin | -38.74% |
| Profit Margin | -37.98% |
| EBITDA Margin | -14.48% |
| EBIT Margin | -26.85% |
| FCF Margin | -30.07% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.11% |
| FCF Yield | -10.36% |
Analyst Forecast
The average price target for XERS is $5, which is 56.7% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5 |
| Price Target Difference | 56.7% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -1.58 |
| Piotroski F-Score | 2 |